Floatz logo

Sofosbuvir

With or Without Liver Decompensation

Gilead SciencesSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the With or Without Liver Decompensation cohort.

Asset / SponsorPhaseRating
Noradrenaline
University of California, Los Angeles
Phase 4BB
Giapreza
University of California, Los Angeles
Phase 4BB
Genotropin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 2/3B
Ribavirin
Gilead Sciences
Phase 2B
rtx001
Resolution Therapeutics Limited
Phase 1/2CCC

View all 10 →

Same molecule, other indications

Sofosbuvir is also rated in:

hepatitis C virus infectionDormant
A
Indicative ·
82 / 100
View asset →
chronic hepatitis C virus infectionDormant
A
Indicative ·
81 / 100
View asset →
cirrhosis of liverDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →